AUTL - Autolus Therapeutics plc - ADR
IEX Last Trade
3.93
0.120 3.053%
Share volume: 347,854
Last Updated: Fri 30 Aug 2024 09:59:55 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
0.21%
PREVIOUS CLOSE
CHG
CHG%
$3.81
0.12
3.15%
Fundamental analysis
5%
Profitability
0%
Dept financing
4%
Liquidity
50%
Performance
0%
Performance
5 Days
-1.50%
1 Month
-12.08%
3 Months
-1.50%
6 Months
-33.73%
1 Year
19.09%
2 Year
16.27%
Key data
Stock price
$3.93
DAY RANGE
N/A - N/A
52 WEEK RANGE
$2.01 - $7.45
52 WEEK CHANGE
$0.18
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
10/31/2024
Company detail
CEO:
Region: US
Website: https://www.autolus.com/
Employees: 411
IPO year: -
Issue type: American Depository Receipt (ADR’s)
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: https://www.autolus.com/
Employees: 411
IPO year: -
Issue type: American Depository Receipt (ADR’s)
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
autolus is a private biopharmaceutical company, focused on the development and commercialisation of engineered t-cell immunotherapy products with extreme efficacy in the treatment of life-threatening cancers. we are building a leading biotechnology company focussed on the development and commercialisation of engineered t-cell therapies for haematological and solid tumours. autolus has the ambition to be a leader of a revolution in medicine in which life-threatening diseases are treated by a patient’s own cells.
Recent news